RT Book, Section A1 Walko, Christine M. A1 Crona, Daniel J. A2 DiPiro, Joseph T. A2 Talbert, Robert L. A2 Yee, Gary C. A2 Matzke, Gary R. A2 Wells, Barbara G. A2 Posey, L. Michael SR Print(0) ID 1164511301 T1 Renal Cell Carcinoma T2 Pharmacotherapy: A Pathophysiologic Approach, 10e YR 2017 FD 2017 PB McGraw-Hill Education PP New York, NY SN 9781259587481 LK accesspharmacy.mhmedical.com/content.aspx?aid=1164511301 RD 2024/03/28 AB Content UpdateJuly 30, 2019Nivolumab plus Ipilimumab for Advanced Renal Cell Carcinoma: In April 2018, the FDA granted approvals to nivolumab and ipilimumab (Opdivo® and Yervoy®) in combination for treatment of intermediate- or poor-risk, previously untreated advanced renal cell carcinoma. Nivolumab is an anti-PD-1 antibody, and ipilimumab is an anti-CTLA-4 antibody. In 2015, nivolumab was approved as subsequent therapy for patients with relapsed or metastatic clear cell histology. The combination of ipilimumab and nivolumab is a NCCN category 1 first-line therapy for patients with intermediate- or poor-risk previously untreated, relapsed, or medically unresectable stage IV clear cell histology renal cell carcinoma.